89-119-503
ZYX, Goat, Polyclonal Antibody, Abnova™
Manufacturer: Abnova Corporation
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | 89-119-503-Each-of-1 | In Stock | ₹ 70,399.00 |
89-119-503 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 70,399.00
GST (18%): ₹ 12,671.82
Total Price: ₹ 83,070.82
Antigen
ZYX
Classification
Polyclonal
Conjugate
Unconjugated
Dilution
ELISA (1:4000) Western Blot (0.1-0.3 ug/mL) The optimal working dilution should be determined by the end user.
Gene
ZYX
Gene Symbols
ZYX
Immunogen
A synthetic peptide corresponding to amino acids at internal region of human ZYX.
Quantity
100 μg
Primary or Secondary
Primary
Target Species
Human
Form
Liquid
Applications
ELISA, Western Blot
Concentration
0.5 mg/mL
Description
Goat polyclonal antibody raised against synthetic peptide of ZYX.
Formulation
In 0.5mg/mL Tris saline, pH 7.3 (0.02% sodium azide, 0.5% BSA)
Gene Alias
ESP-2/HED-2
Host Species
Goat
Purification Method
Antigen affinity purification
Regulatory Status
RUO
Gene ID (Entrez)
7791
Content And Storage
Store at -20°C.Aliquot to avoid repeated freezing and thawing.
Related Products
Description
- Focal adhesions are actin-rich structures that enable cells to adhere to the extracellular matrix and at which protein complexes involved in signal transduction assemble
- Zyxin is a zinc-binding phosphoprotein that concentrates at focal adhesions and along the actin cytoskeleton
- Zyxin has an N-terminal proline-rich domain and three LIM domains in its C-terminal half
- The proline-rich domain may interact with SH3 domains of proteins involved in signal transduction pathways while the LIM domains are likely involved in protein-protein binding
- Zyxin may function as a messenger in the signal transduction pathway that mediates adhesion-stimulated changes in gene expression and may modulate the cytoskeletal organization of actin bundles
- Alternative splicing results in multiple transcript variants that encode the same isoform
- [provided by RefSeq Sequence: C-QQREKPRVQEKQH